Nov 15, 2019 - 3:15pm

Pfizer Implemented More than 4,000 Greenhouse Gas Reduction Projects Since 2000


  • As a science-focused, global, innovative, biopharmaceutical company, Pfizer has taken progressive steps to reduce greenhouse gas (GHG) emissions associated with its operations in recognition of the scientific consensus regarding the causes of climate change and its adverse health and environmental impacts. Pfizer has had public GHG reduction goals since 2000. From 2000 to 2007, the company reduced its GHG emissions 16%. From 2007 to 2012, the company reduced its emissions an additional 27%.
  • Pfizer is on track to achieve its current goal, one of the first to be recognized as a Science-Based Target, to reduce GHG emissions 20% by 2020 (from a 2012 baseline), enabling the company to stay on a trajectory to reduce emissions 60% to 80% by 2050 (from a 2000 baseline).
  • The company is committed to continuing to implement GHG emissions and other resource use reduction projects and developing new climate goals based on the latest science.
  • Recognizing its significant and wide-reaching supply chain, Pfizer is committed to continuing to work with key supply chain partners to help them establish science-based GHG reduction targets.


  • Pfizer has implemented more than 4,000 greenhouse gas reduction projects since 2000, including the following:
    • Installation of two wind turbines, which produce approximately 15% of the electricity consumed by Pfizer’s site in Puurs, Belgium.
    • Solar installations at facilities in California, Connecticut, Italy, Singapore, and China.
    • Execution of solar power purchase agreements in Puerto Rico and New Jersey.
    • Installation of new equipment at its facility in Rocky Mount, North Carolina, to improve efficiency, reducing GHG emissions by 50,000 million tons.
    • Replacement of boilers at its Kalamazoo, Michigan, site, which will result in GHG emission reductions by 40,000 million tons.
    • Five of Pfizer’s manufacturing sites have achieved ISO 50001 certification of energy management systems.
    • LEED Platinum certification was achieved for its newly constructed manufacturing facility in Dalian, China.


  • Through application of green chemistry principles and manufacturing innovation, Pfizer has improved the environmental footprint of certain key products. For example, the application of biocatalysis, (enabling replacement of solvent with aqueous systems) has delivered improvements in environmental performance for a number of commercial products, including the following:
    • Lipitor: process changes yielded approximately 65% solvent reduction and >50% energy reduction. 
  • Pfizer continues to be an early adopter of new technology. For example, it is introducing continuous manufacturing, including FAST technology for active pharmaceutical ingredients, and Portable Continuous Modular Manufacturing for drug products. It has been demonstrated that the application of FAST technology is transformative, compared with typical batch manufacturing processes, potentially reducing energy consumption up to 30% and solvent use up to 80%. 

For more information, visit

More Articles On: